By the physicians of Amanecia Health | Updated April 27, 2026
Last reviewed June 18, 2026 by Ann Czarnik, M.D., FACEP. This page is maintained as a living reference and updated as the FDA process develops.
Related: Read our follow-up on the NPR report on peptide restrictions and what it means for patients.
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. publicly addressed FDA action on a group of peptide substances that had been on the FDA’s Category 2 restricted compounding list. The companies that originally nominated those peptides for that list have since withdrawn their nominations. The FDA announced the action on April 15, 2026 (Federal Register notice April 16), and the peptides come off the Category 2 list effective April 23, 2026.. The FDA’s Pharmacy Compounding Advisory Committee will review whether to officially clear any of them for compounding at its July 23-24, 2026 meeting.
For patients who rely on peptide therapy for recovery, immune support, metabolic health, and longevity, this is significant news. But it also comes with an important caveat that isn’t getting enough attention: this regulatory change is not the same as FDA approval, and how you access these therapies matters just as much as whether you can.
FDA peptide action: what changed and when
- April 15, 2026 — the FDA announced the action (Federal Register notice April 16, 2026).
- April 23, 2026 — effective date: twelve peptides come off the Category 2 “do not compound” list, after their nominations were withdrawn.
- July 23-24, 2026 — the Pharmacy Compounding Advisory Committee reviews seven peptides for eligibility to be compounded under section 503A.
- By end of February 2027 — a later PCAC meeting reviews five additional peptides.
What Changed, and What Didn’t
In late 2023, the FDA moved 19 widely used peptides to its Category 2 list, effectively banning compounding pharmacies from preparing them. The stated rationale was safety concerns, though many clinicians and compounding pharmacy groups argued the agency overstepped, noting that no specific safety signal justified the restriction for most of the affected peptides.
Removal from Category 2 is a step, not a clearance. The FDA still has specific criteria a substance must meet to be eligible for compounding, and the Pharmacy Compounding Advisory Committee’s July 2026 review will determine whether any of these peptides will be officially cleared. Even where compounding becomes permitted, it does not mean these peptides are FDA-approved drugs. They remain prescription therapeutics used under physician supervision, with proper dosing and ongoing monitoring.
Among the twelve peptides removed from the Category 2 list (effective April 23, 2026):
Removal from Category 2 is separate from the FDA’s review of which peptides may be compounded under section 503A. At its July 23-24, 2026 meeting, the FDA’s Pharmacy Compounding Advisory Committee reviews seven peptides for 503A eligibility: on July 23, BPC-157, KPV, TB-500, and MOTS-C; on July 24, Emideltide (also called DSIP), Semax, and Epitalon. Five additional peptides go to a later PCAC meeting before the end of February 2027. Coming off Category 2, being reviewed for 503A, and FDA drug approval are three different things.
-
- BPC-157 — tissue repair, gut lining health, tendon/ligament recovery, localized inflammation.
- TB-500 (Thymosin Beta-4 fragment) — muscle recovery, flexibility, connective-tissue repair.
- GHK-Cu (copper peptide) — skin remodeling, wound healing, hair-follicle support.
- MOTS-C — mitochondrial function, metabolic regulation, cellular energy.
- Epitalon — pineal-derived; circadian rhythm and longevity markers (early-stage).
- Semax — neuropeptide; cognitive performance, focus, neuroprotection.
- DiHexa — cognitive support and neural connectivity (early-stage).
- DSIP (Delta Sleep-Inducing Peptide) — sleep architecture and stress response.
- KPV — anti-inflammatory; gut inflammation and immune regulation.
- LL-37 — antimicrobial peptide; immune modulation (narrow use case).
- PEG-MGF (pegylated mechano growth factor) — muscle repair and recovery.
- Melanotan II — skin pigmentation; Amanecia does not prescribe it for cosmetic tanning.
Why This Matters, and Why It’s Not a Free-for-All
The Category 2 restrictions didn’t eliminate demand for these peptides. They pushed patients toward unregulated gray-market sources: “research use only” vendors with no pharmaceutical oversight, no quality control, and no guarantee of purity or correct dosing. Kennedy himself acknowledged this directly, stating that the restrictions “created the gray market.”
Removal from Category 2 is a step toward potentially restoring safe, regulated access, depending on what the PCAC review concludes in July. Either way, safe access depends on two things: the quality of the compounding pharmacy preparing the peptide, and the physician overseeing the therapy.
This is where the difference between buying peptides online and receiving peptide therapy under physician supervision becomes critical.
How Amanecia Health Approaches Peptide Therapy
At Amanecia Health, peptide therapy is not a product we sell. It’s a treatment we prescribe, monitor, and adjust based on each patient’s individual health profile and goals. Every peptide protocol is designed and overseen by a board-certified Emergency Medicine physician.
Our approach includes:
-
- Clinical evaluation before prescribing : We assess your health history, current medications, lab results, and treatment goals before recommending any peptide therapy.
-
- Sourcing from licensed, compliant pharmacies : All peptides are sourced from FDA-registered, U.S.-based compounding pharmacies that comply with USP 797 and 795 standards.
-
- Ongoing monitoring and dose adjustment : Peptide therapy isn’t one-size-fits-all. We monitor your response, adjust dosing, and ensure your protocol evolves with your health.
-
- Integration with your broader care : Peptide therapy works best as part of a comprehensive wellness plan. Our physicians coordinate it alongside other treatments and health priorities.
What Patients Should Know Right Now
The FDA’s formal action takes effect April 23, 2026, with the PCAC review of these substances scheduled for July 23-24, 2026. In the meantime:
-
- Don’t rush to gray-market sources. Working with a physician and a licensed compounding pharmacy provides quality control and oversight that gray-market sources cannot.
- Work with a physician, not an influencer. Peptide dosing, timing, and combination protocols require medical expertise. Social media is full of peptide advice from people without clinical training.
- Ask about sourcing. Not all compounding pharmacies are equal. Ask your provider where their peptides come from and whether the pharmacy holds current USP compliance.
- Understand what “not FDA-approved” means. Even when peptides become eligible for compounding, they have not gone through the clinical trial process required for FDA drug approval. They remain prescription therapeutics used under physician discretion.
The Bottom Line
The shifting regulatory picture is potentially good news for patients who benefit from peptide therapies, depending on PCAC’s July decision. But the biggest risk was never the peptides themselves. It was unregulated access without physician oversight, and that risk doesn’t go away no matter what the regulatory status becomes.
If you’re interested in peptide therapy for recovery, immune support, metabolic health, or longevity, the right move is to work with a physician who can evaluate whether it’s appropriate for you, prescribe the correct protocol, and monitor your progress.
Amanecia Health offers physician-led peptide therapy delivered in your home or via telemedicine. Our board-certified Emergency Medicine physicians are available to discuss whether peptide therapy is right for your health goals.
FDA Peptide Reclassification: Common Questions
What did the FDA do to peptides in 2026?
Effective April 23, 2026, the FDA removed twelve peptides from its Category 2 restricted compounding list after the original nominations were withdrawn, which eases the restriction on compounding them. Separately, its Pharmacy Compounding Advisory Committee reviews seven peptides for section 503A compounding eligibility on July 23-24, 2026. Neither step makes these peptides FDA-approved drugs.
Are these peptides FDA approved now?
No. Coming off the Category 2 list is not FDA drug approval, and it is not the same as being cleared for compounding under section 503A. None of these peptides has completed the clinical trial and approval process. They remain prescription therapeutics that should be physician-managed and pharmacy-sourced.
Which peptides are being reviewed at the July 2026 PCAC meeting?
Seven peptides are on the July 23-24, 2026 agenda for section 503A review: BPC-157, KPV, TB-500, and MOTS-C on July 23, and Emideltide (DSIP), Semax, and Epitalon on July 24. Five more peptides are scheduled for a later PCAC meeting before the end of February 2027. The committee makes recommendations to the FDA rather than approving the peptides itself.
Is BPC-157 legal in 2026?
BPC-157 came off the FDA Category 2 list effective April 23, 2026, and is one of the seven peptides under PCAC review for 503A compounding eligibility in July 2026. It is not an FDA-approved drug and is not a legal over-the-counter supplement. Legitimate access runs through a licensed physician and a compounding pharmacy, under medical supervision.
Is Semax legal in the US?
Semax came off the Category 2 list in 2026 and is also one of the seven peptides under PCAC review in July 2026. It is not an FDA-approved drug and not a legal over-the-counter supplement. Access depends on physician involvement and pharmacy sourcing; patients should not buy it from unregulated online sellers.
What about GHK-Cu (copper peptide)?
GHK-Cu is among the peptides removed from Category 2 in 2026 and is used in some compounded and topical formulations. It is not an FDA-approved drug for systemic therapeutic use. The therapeutic compounded form should be physician-directed and pharmacy-sourced, not bought from gray-market suppliers.
Is it safe to order peptides online?
No. Many online sources are unregulated, and purity, dosing, sterility, and contamination are real risks. Peptides should be obtained through a physician evaluation and a licensed compounding pharmacy that meets USP 795 and 797 standards, not from a website that ships without a prescription.
Related Reading
- Peptide Therapy: A Physician’s Guide to Patient Benefits
- Peptides Back in the News: What Actually Matters
- Wellness and Longevity at Amanecia Health
Amanecia Health provides concierge medicine services including peptide therapy, weight loss medications, hormone replacement therapy, in-home urgent care, and telemedicine visits across Austin, Houston, Dallas–Fort Worth, and Coastal Virginia. All care is delivered by board-certified Emergency Medicine physicians.
Note: Compounded peptides are not FDA-approved drugs. They are prepared by licensed compounding pharmacies under physician prescription and have not been evaluated through clinical trials for safety, efficacy, or therapeutic equivalence to any FDA-approved medications. This content is for informational purposes and does not constitute medical advice.